
    
      Eligible participants will be randomized to receive either imatinib mesylate or placebo
      daily.

      All participants randomized into this study will be seen at a study site for a follow-up
      evaluation, 2 weeks and 4 weeks after randomization, and every month month thereafter for the
      first year. Participants will come in for a visit ever 6 months for the second year.

      At the study visits, participants will undergo assessments of their insulin production,
      immunologic status, and overall health. Subjects will be followed until the conclusion of the
      study. The trial is expected to last approximately 2-4 years or until the required amount of
      information is gathered.
    
  